Preclinical development

A new digital article is now available to download entitled ‘A comprehensive approach to immunophenotyping for targeted drug discovery and development’.  With high costs of therapeutic development, success relies on optimising preclinical and early clinical studies. Download this content-rich digital article to read about considerations for implementing and standardising high-dimensional immune profiling methods into drug […]

With high costs of therapeutic development, success relies on optimising preclinical and early clinical studies. Download this content-rich digital article to read about considerations for implementing and standardising high-dimensional immune profiling methods into drug development programs. Learn about different applications that demonstrate the robustness and reproducibility of a mass cytometry-based analysis to deeply interrogate complex […]

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more.  As CSO, Professor Blackburn heads the R&D and product development strategy. He invented the patented Sengenics K-REX technology, holds more than 30 technology […]

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more.  As CSO, Professor Blackburn heads the R&D and product development strategy. He invented the patented Sengenics K-REX technology, holds more than 30 technology […]

The latest sponsored DDW Sitting Down With podcast is now available. It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance of evaluating seizure […]

The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance of evaluating seizure liability. The speakers outline […]

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective […]

New study results show that an experimental drug may prevent or slow vision loss in people with diabetes. The researchers at Wilmer Eye Institute, Johns Hopkins Medicine used mouse as well as human retinal organoids and eye cell lines in their investigations. Eye conditions that cause vision loss are common complications of diabetes, affecting nearly […]

PerkinElmer’s Life Science and Diagnostics business has revealed its new name and branding. Revvity has now officially launched as a science-based solutions company. Based on two words, ‘revolutionise’ (rev) and ‘vita’ (vit) meaning ‘life’ in Latin, Revvity will provide reagents, consumables, assays, instruments and software to customers from pharma and biotech, diagnostic labs, academia and government […]

Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable alternatives are available, has highlighted […]

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. While the global proteasome inhibitors market is expected to […]

BioIVT has acquired XenoTech, a provider of products and services for preclinical testing that specialises in ADME, DMPK and DDI testing of potential drug candidates.  Through the acquisition, BioIVT aims to expand the portfolio of research models and services that are available to its clients to support their R&D function.   “XenoTech has a well-established and excellent reputation […]

Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. The company’s NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins and is being developed alongside GNA NOW, a European Consortium funded by the Innovative Medicines Initiative 2 (IMI2). Discovered by […]

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application Science Team Lead, Carterra.  The background  […]

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of preclinical development, hosted by DDW […]

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals discusses translational immuno-oncology assay development in […]